| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
CAMBRIDGE, U.K.—PhoreMost Ltd., a biopharmaceutical company dedicated to drugging “undruggable” disease targets, and Sentinel Oncology, in early November announced an expansion of their collaboration to accelerate the progression of SOL686, a novel allosteric Polo-like kinase 1 (PLK1) inhibitor through preclinical development and IND-enabling studies for the treatment of glioma.
 
Mitotic PLKs are widely recognized as playing crucial roles in disease causing pathways, including K-Ras mutant cancers, the companies notes. Traditional approaches to drugging PLK enzymes have focused on targeting their active site; however this tactic has been hindered by toxicity-associated adverse events. Sentinel Oncology’s allosteric PLK1 inhibitor takes the novel approach of targeting the Polo-box domain of the PLKs, thereby aiming to mitigate adverse events seen by active site inhibitors.
 
The program has reportedly demonstrated a promising combination of specific drug-like properties, mode of action and target validation data obtained so far. Originating from the laboratory of Prof. Ashok Venkitaraman at the University of Cambridge, PhoreMost subsequently developed the lead chemical series. Sentinel Oncology then optimized drug-like properties for the series and guided therapeutic positioning. Both PhoreMost and Sentinel Oncology received funding from Innovate UK for the drug discovery program.
 
“We are delighted to deepen our long-standing association with Sentinel Oncology, and excited to be progressing this drug discovery program towards the clinic,” said Dr. Chris Torrance, CEO of PhoreMost. “This lead compound exemplifies the value of PhoreMost’s strategy to use functional protein-protein interactions to drive the development of novel therapies, and to capitalise on its SITESEEKER platform to change the model of drug discovery through innovation, strategic partnerships and collaboration.”
 
Commented Robert Boyle, CEO of Sentinel Oncology: “We are very excited about the prospects for this program, and to be collaborating with PhoreMost to advance our allosteric PLK1 inhibitor. The program adds to our neuro-oncology pipeline, has started formal preclinical studies and is well positioned to enter clinical development as a glioma treatment by 2021.”

Related Topics

Published In

Volume 15 - Issue 12 | December 2019

December 2019

December 2019 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Reliable fluid biomarkers strategies for clinical neuroscience research

Reliable fluid biomarkers strategies for clinical neuroscience research

Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
A group of blue capsules is scattered on a bright yellow surface, with one capsule opened to reveal white powder inside.

Understanding drug impurities: types, sources, and analytical strategies

Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue